$OPCH

Option Care Health, Inc. Stock 12‑Month Price Target Raised to $28.91, Implies 24% Upside

Analysts raised the 12-month price target for Option Care Health, Inc. from $28.58 to $28.91, suggesting a 24% upside. The consensus rating remains 'Buy' with 9 Buys, 4 Holds, and 0 Sells. The forecasts range from $23 to $39 per share, according to 11 analysts.

Original reporting
Published Oct 6, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 4:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Option Care Health, Inc. Stock 12‑Month Price Target Raised to $28.91, Implies 24% Upside — source image
Decision brief

The 30-second read

$OPCHBullishLow
01

Why it matters

Analyst consensus remains a Buy, with a modest upward revision to price targets.

02

Market read

The target raise may generate modest buying interest but lacks a catalyst for significant price movement.

03

What to watch

No new operational or financial data accompanies the target change.

Relevance 6/10Novelty 5/10Timing: today

Background

Option Care Health provides home health and hospice services; its stock trades on the NYSE under OPCH.

Company-level read

Ticker impact

$OPCHBullishMedium confidence
Context

Analysts raised the average 12‑month price target to $28.91, implying ~24% upside.

Expected impact

potential upside as investors price in the higher target

Evidence & confidence

Target raise is modest and reflects incremental analyst optimism; no new catalyst beyond the rating change.

Market effects

Minor positive signal for the healthcare services sector.

Limited to U.S. small‑cap healthcare stocks.

Low

Counterpoint

Target raises may be premature if underlying earnings growth does not materialize.

Key entities

  • Option Care Health, Inc.

    U.S.-listed provider of home health and hospice services.

Related articles

$OPCHHighAI 9/10

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.

$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.